Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ravi Salgia

Showing results (401-410 of 529) with videos related to

Pageof 53
Sort By:
Iscience|November 16, 2020
Activation of EPHA2-ROBO1 Heterodimer by SLIT2 Attenuates Non-canonical Signaling and Proliferation in Squamous Cell CarcinomasSaumya Srivastava, Ka Ming Pang, Mari Iida, et al.
Cancer Biology & Therapy|November 18, 2015
C. elegans and mutants with chronic nicotine exposure as a novel model of cancer phenotypeRajani Kanteti, Immanuel Dhanasingh, Essam El-Hashani, et al.
Cancer Biology & Therapy|January 6, 2018
Focal adhesion kinase a potential therapeutic target for pancreatic cancer and malignant pleural mesotheliomaRajani Kanteti, Tamara Mirzapoiazova, Jacob J Riehm, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 14, 2010
Phase II study of amrubicin as second-line therapy in patients with platinum-refractory small-cell lung cancerDavid S Ettinger, Robert Jotte, Paul Lorigan, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|September 2, 2008
Phase I trial of erlotinib-based multimodality therapy for inoperable stage III non-small cell lung cancerNicholas W Choong, Ann M Mauer, Daniel J Haraf, et al.
European Journal of Nuclear Medicine and Molecular Imaging|September 28, 2011
Prognostic value of metabolic tumor burden on 18F-FDG PET in nonsurgical patients with non-small cell lung cancerShengri Liao, Bill C Penney, Kristen Wroblewski, et al.
Cancer Letters|June 22, 2022
Endothelin-axis antagonism enhances tumor perfusion in pancreatic cancerShailendra K Gautam, Vipin Dalal, Balasrinivasa R Sajja, et al.
Anesthesia and Analgesia|December 16, 2010
The novel role of the mu opioid receptor in lung cancer progression: a laboratory investigationBiji Mathew, Frances E Lennon, Jessica Siegler, et al.
International Journal of Oncology|April 3, 2020
Effects of selected deubiquitinating enzyme inhibitors on the proliferation and motility of lung cancer and mesothelioma cell linesTamara Mirzapoiazova, Alexander Pozhitkov, Arin Nam, et al.
Future Oncology (London, England)|November 29, 2019
Dose-escalation trial of the ALK, MET & ROS1 inhibitor, crizotinib, in patients with advanced cancerJeffrey W Clark, D Ross Camidge, Eunice L Kwak, et al.
Pageof 53

Showing results (401-410 of 529) with videos related to

Sort By:
Pageof 53
Iscience|November 16, 2020
Activation of EPHA2-ROBO1 Heterodimer by SLIT2 Attenuates Non-canonical Signaling and Proliferation in Squamous Cell CarcinomasSaumya Srivastava, Ka Ming Pang, Mari Iida, et al.
Cancer Biology & Therapy|November 18, 2015
C. elegans and mutants with chronic nicotine exposure as a novel model of cancer phenotypeRajani Kanteti, Immanuel Dhanasingh, Essam El-Hashani, et al.
Cancer Biology & Therapy|January 6, 2018
Focal adhesion kinase a potential therapeutic target for pancreatic cancer and malignant pleural mesotheliomaRajani Kanteti, Tamara Mirzapoiazova, Jacob J Riehm, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 14, 2010
Phase II study of amrubicin as second-line therapy in patients with platinum-refractory small-cell lung cancerDavid S Ettinger, Robert Jotte, Paul Lorigan, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|September 2, 2008
Phase I trial of erlotinib-based multimodality therapy for inoperable stage III non-small cell lung cancerNicholas W Choong, Ann M Mauer, Daniel J Haraf, et al.
European Journal of Nuclear Medicine and Molecular Imaging|September 28, 2011
Prognostic value of metabolic tumor burden on 18F-FDG PET in nonsurgical patients with non-small cell lung cancerShengri Liao, Bill C Penney, Kristen Wroblewski, et al.
Cancer Letters|June 22, 2022
Endothelin-axis antagonism enhances tumor perfusion in pancreatic cancerShailendra K Gautam, Vipin Dalal, Balasrinivasa R Sajja, et al.
Anesthesia and Analgesia|December 16, 2010
The novel role of the mu opioid receptor in lung cancer progression: a laboratory investigationBiji Mathew, Frances E Lennon, Jessica Siegler, et al.
International Journal of Oncology|April 3, 2020
Effects of selected deubiquitinating enzyme inhibitors on the proliferation and motility of lung cancer and mesothelioma cell linesTamara Mirzapoiazova, Alexander Pozhitkov, Arin Nam, et al.
Future Oncology (London, England)|November 29, 2019
Dose-escalation trial of the ALK, MET & ROS1 inhibitor, crizotinib, in patients with advanced cancerJeffrey W Clark, D Ross Camidge, Eunice L Kwak, et al.
Pageof 53